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A B S T R A C T   
Background and aims: Lipoprotein particle size is associated with increased atherosclerosis and cardiovascular 
disease risk. Certain lifestyle behaviours may be cardioprotective. We examined lipoprotein particle size and 
concentration relationships with a protective lifestyle behaviour (PLB) score. 
Methods: This was a cross-sectional analysis of 2045 middle-to older-aged adults. Lipoprotein particle subclass 
size and concentrations were determined using nuclear magnetic resonance spectroscopy. Five protective be-
haviours included never smoking, moderate alcohol intake, moderate to vigorous physical activity, a high-quality 
diet (upper 40% Dietary Approaches to Stop Hypertension score) and a normal body mass index (BMI) 
(18.5–24.9 kg/m2). Linear and logistic regression analyses tested individual protective behaviour and PLB score 
associations with lipoprotein subclasses. 
Results: Individual behaviour associations varied according to lipoprotein subclass, with normal BMI showing the 
greatest number of significant relationships. Logistic regression analyses revealed that subjects with the fewest 
number of protective behaviours had 1.4–2.8 increased odds of having less favourable lipoprotein profiles 
defined as above or below median level lipoprotein particle subclass size or concentration. Following additional 
adjustment for BMI, significant trend relationships were observed between the PLB score and large and medium 
very low-density lipoprotein (p = 0.001 and p < 0.001), total and smaller low-density lipoprotein (LDL) con-
centrations (p = 0.008 and p < 0.001), LDL size (p = 0.003) and a lipoprotein insulin resistance score (p = 0.003). 
Conclusions: Results show a cumulative protective effect of healthy lifestyle behaviours against an unfavourable 
potentially pro-atherogenic lipoprotein profile in middle-to older-aged adults, highlighting the importance of 
lifestyle promotion in healthy ageing.   
1. Introduction 
Chronic non-communicable diseases are reaching epidemic pro-
portions worldwide [1] and are a major public health concern. The 
causal role of high cholesterol concentrations in the pathogenesis of 
chronic conditions is well established. Obesity and insulin resistance are 
linked to alterations in the lipoprotein particle profile and this may in-
fluence type 2 diabetes and cardiovascular disease (CVD) risk [2–4]. 
Traditional lipid tests quantify the cholesterol or triglyceride content of 
lipoproteins, and the amount of cholesterol carried by lipoprotein par-
ticles is thought to be an important parameter for estimating disease risk 
[5]. However, traditional cholesterol levels may not accurately reflect 
the true atherogenicity of plasma lipid profiles. 
Nuclear magnetic resonance (NMR) spectroscopy simultaneously 
quantifies the number and size of lipoprotein particles [6]. Lipoprotein 
particle size, in particular smaller low-density lipoprotein (LDL) and 
high-density lipoprotein (HDL) particles and large very low-density li-
poprotein (VLDL) particles, has been shown to be associated with 
increased risk for atherosclerosis and premature CVD [2,7,8]. We have 
also shown increased likelihood of being metabolically healthy among 
obese and non-obese adults with favourable lipoprotein profiles char-
acterised by less large VLDL and smaller LDL and more large LDL and 
HDL particles [9]. 
Research studies have demonstrated relationships between modifi-
able health behaviours and morbidity and mortality [10–13]. Obesity, 
high levels of alcohol consumption and smoking have been shown to 
increase the risk of morbidity [14,15], whereas moderate-to-high levels 
of physical activity and healthy diet have been shown to reduce the risk 
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[16–18]. Since increased or decreased levels of these factors provide 
protection and prevent the likelihood of negative outcomes they have 
also been termed as protective lifestyle behaviours (PLB) [19]. 
A recent large study in the United States revealed that adhering to 
five low-risk behaviours may prolong life expectancy by 12.2 and 14 
years for men and women, respectively – in comparison to those with no 
protective behaviours [20]. However, the mechanism for this associa-
tion remains unclear. Although a number of studies have examined re-
lationships between individual protective behaviours and lipoprotein 
concentrations, the focus on lipoprotein profiling in this context has 
been restricted to a narrow range of markers. In addition, no research to 
date has examined the cumulative effect of protective behaviours on 
lipoprotein subclasses. 
Therefore, the main objective of this study was to fully examine li-
poprotein particle size and concentration relationships with a 5-compo-
nent PLB score (never smoking, moderate alcohol intake, moderate or 
high physical activity levels, healthy diet and healthy weight), using a 
cross-sectional sample of 2045 middle-to older-aged men and women, to 
determine whether the number of protective behaviours is related to 
lipoprotein subclass measures. 
2. Materials and methods 
2.1. Study population and setting 
The Cork and Kerry Diabetes and Heart Disease Study (Phase II – 
Mitchelstown Cohort) was a single centre study conducted between 
2010 and 2011. A random sample was recruited from a large primary 
care centre in Mitchelstown, County Cork, Ireland. The Living Health 
Clinic serves a population of approximately 20,000 Caucasian-European 
subjects, with a mix of urban and rural residents. Stratified sampling was 
employed to recruit equal numbers of men and women from all regis-
tered attending patients in the 46–73-year age group. In total, 3807 
potential participants were selected from the practice list. Following the 
exclusion of duplicates, deaths and subjects incapable of consenting or 
attending appointment, 3051 were invited to participate in the study 
and of these, 2047 (49% male) completed the questionnaire and phys-
ical examination components of the baseline assessment (response rate: 
67%). Data on protective lifestyle behaviours were available for 2045 
subjects. Details regarding the study design, sampling procedures and 
methods of data collection have been reported previously [21]. 
Ethics committee approval conforming to the Declaration of Helsinki 
was obtained from the Clinical Research Ethics Committee of University 
College Cork. A letter signed by the contact GP in the clinic was sent out 
to all selected participants with a reply slip indicating acceptance or 
refusal. All subjects gave signed informed consent, including permission 
to use their data for research purposes. 
2.2. Clinical procedures 
Study participants attended the clinic in the morning after an over-
night fast and blood samples were taken on arrival. Fasting glucose and 
glycated haemoglobin A1c (HbA1c) concentrations were measured by 
Cork University Hospital Biochemistry Laboratory using standardised 
procedures and fresh samples. Glucose concentrations were determined 
using a glucose hexokinase assay (Olympus Life and Material Science 
Europa Ltd., Lismeehan, Co. Clare, Ireland) and HbA1c levels were 
measured in the haematology laboratory on an automated high-pressure 
liquid chromatography instrument Tosoh G7 [Tosoh HLC-723 (G7), 
Tosoh Europe N.V, Tessenderlo, Belgium]. 
Anthropometric measurements were performed by trained re-
searchers with reference to a standard operating procedures manual. 
Height was measured with a portable Seca Leicester height/length sta-
diometer (Seca, Birmingham, UK) and weight was measured using a 
portable electronic Tanita WB-100MA weighing scale (Tanita Corp, IL, 
USA). The weighing scale was placed on a firm flat surface and was 
calibrated weekly. Body mass index (BMI) was calculated as weight in 
kilograms divided by the square of height in meters. 
2.3. Lipoprotein profiling 
Lipoprotein subclass particle concentrations and average VLDL, LDL 
and HDL particle diameters were measured on serum specimens by NMR 
spectroscopy at LipoScience, Inc (Raleigh, NC). VLDL, LDL and HDL 
subclasses were quantified based on the amplitudes of their 
spectroscopically-distinct lipid methyl group NMR signals [6]. 
Weighted-average VLDL, LDL and HDL particle sizes (in nanometre 
diameter units) were computed as the sum of the diameter of each 
subclass multiplied by its relative mass percentage as estimated from the 
amplitude of its NMR signal. The following subclass categories were 
investigated: large VLDL (including chylomicrons, if present) (>60 nm), 
medium VLDL (42–60 nm), small VLDL (29–42 nm), 
intermediate-density lipoprotein [IDL] (25–35 nm), large LDL (20.5–23 
nm), small LDL (18–20.5 nm), large HDL (9.4–14 nm), medium HDL 
(8.2–9.4 nm) and small HDL (7.3–8.2 nm). Particle concentrations are 
expressed as nanomoles per litre (VLDL and LDL) and micromoles per 
litre (HDL). A Lipoprotein Insulin Resistance score (LP-IR), ranging from 
0 (least) to 100 (most) insulin resistant, which is a weighted combina-
tion of the six lipoprotein subclass and size parameters most closely 
associated with insulin resistance, was calculated [22]. 
2.4. Data collection 
A general health and lifestyle questionnaire assessed demographic 
variables, lifestyle behaviours and morbidity. Information on age, sex, 
education, medication use, smoking status, alcohol drinking habits and 
presence of type 2 diabetes was provided by participants. Physical ac-
tivity levels were measured using the validated International Physical 
Activity Questionnaire (IPAQ) [23]. 
A validated Food Frequency Questionnaire (FFQ) consisting of 150 
different food items was used for dietary assessment [24,25]. The 
average medium serving of each food item consumed by participants 
over the last 12 months was converted into quantities using standard 
portion sizes. Food item quantity was expressed as (gm/d) and bever-
ages as (ml/d). Based on the FFQ, the Dietary Approaches to Stop Hy-
pertension (DASH) diet score was constructed [26]. DASH is a dietary 
pattern rich in fruits, vegetables, whole grains and low-fat dairy foods 
and is limited in sugar-sweetened foods and beverages, red meat and 
added fats. This diet has been promoted by the National Heart, Lung and 
Blood Institute (part of the National Institutes of Health, a United States 
government organisation) to prevent and control hypertension. DASH 
diet scores ranged from 11 to 42. Lower scores represent poorer and 
higher scores represent better quality diet [17]. Dietary fat (percent 
energy intake) was calculated from food frequency questionnaire 
responses. 
2.5. Classification and scoring of variables 
2.5.1. Exposure: protective behaviours 
We classified protective behaviours according to the same method-
ology as used previously in research by our group [27]. Smoking status 
was defined as follows: (i) never smoked, i.e. having never smoked at 
least 100 cigarettes (5 packs) in their entire life; (ii) former smoker, i.e. 
having smoked 100 cigarettes in their entire life and do not smoke at 
present; and (iii) current smoker, i.e. smoking at present. These defini-
tions were the same as those used in the SLÁN National Health and 
Lifestyle Survey [28]. A binary variable was then created: ‘never/former 
smoker’ or ‘current smoker’. For the purpose of the present analysis, 
‘never/former smoker’ was compared with ‘current smoker’, with the 
former being defined as a protective behaviour. 
Alcohol consumption was measured in units of alcohol consumed on 
a weekly basis and was categorised into the following levels: (i) non- 
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drinker, i.e. <1 drink per week; (ii) moderate drinker, i.e. between 1 and 
14 drinks per week; and (iii) heavy drinker, i.e. >14 drinks per week. 
Moderate drinker was defined on the basis of previous work from the 
European Prospective Investigation into Cancer and Nutrition (EPIC) in 
the United Kingdom by Khaw et al. [29]. For the current analysis, these 
were then re-categorised as ‘moderate/non-drinker’ or ‘heavy drinker’, 
with the former being defined as a healthy lifestyle behaviour. 
Physical activity was categorised as low, moderate and high levels of 
activity using the IPAQ. This was then recoded as a dichotomous vari-
able: ‘moderate/high’ or ‘low’ physical activity, with ‘moderate/high’ 
levels of physical activity being defined as a protective behaviour. We 
classified a healthy diet as a DASH diet score in the top 40% for the study 
sample. Normal body weight was defined as a BMI in the range 
18.5–24.9 kg/m2. 
A protective lifestyle behaviour (PLB) score was constructed using 
the same method as described in recent research by Li et al. [20]. For 
each low-risk behaviour, the participant received a score of 1 if they met 
the criterion for low risk. If the participant did not meet the criterion, 
they were classified as high risk for that factor and received a score of 0. 
The sum of these five scores provided a total number of low-risk be-
haviours of 0, 1, 2, 3, 4 or 5, with higher scores indicating a healthier 
lifestyle. The PLB score was then re-coded into a four-category variable: 
‘0 or 1’; ‘2’; ‘3’; and ‘4 or 5’ protective behaviours. 
2.5.2. Confounding variables 
Based on the literature, potential confounders considered included 
age, sex, morbidity (type 2 diabetes) and education. Type 2 diabetes was 
determined as a fasting glucose level ≥7.0 mmol/l or a HbA1c level 
≥6.5% (≥48 mmol/mol) [30] or by self-reported diagnosis. Categories 
of education included ‘some primary (not complete)’, ‘primary or 
equivalent’, ‘intermediate/group certificate or equivalent’, ‘leaving 
certificate or equivalent’, ‘diploma/certificate’, ‘primary university de-
gree’ and ‘postgraduate/higher degree’. These were collapsed and 
recoded into a dichotomous variable: ‘primary education only’ and 
‘intermediate or higher’. 
Statin use and energy intake were also considered as potential con-
founders. However, neither variable demonstrated an association with 
the PLB score and adjustment for these variables in analyses did not 
change our results. 
2.5.3. Statistical analysis 
Descriptive characteristics were examined according to sex and by 
the number of protective behaviours. Categorical features are presented 
as percentages and continuous variables are shown as a mean (plus or 
minus one standard deviation) or a median and interquartile range for 
skewed data. Differences between protective behaviour groups were 
analysed using an ANOVA or Jonckheere trend test for continuous 
variables or with a linear-by-linear chi-square for categorical features. 
The relationships between a PLB score and lipoprotein concentrations 
were examined using Spearman’s rank-order correlation. 
Skewed data were log-transformed and linear regression was utilised 
to determine individual protective behaviour and PLB score associations 
with lipoprotein subclasses. Two models were run: the first model was 
adjusted for age, sex, education and type 2 diabetes. Models which 
examined individual protective behaviours were additionally adjusted 
for each other. To correct for the multiple testing performed, we 
calculated false discovery rate adjusted p values via the Romano-Wolf 
multiple hypothesis correction method using the rwolf command in 
Stata [31]. 
Logistic regression was used to determine associations between the 
number of protective behaviours and lipoprotein status (categorised as 
above or below median level for each lipoprotein subclass) [9]. The odds 
ratio (OR) for each model with a 95% confidence interval (CI) is 
reported. 
Data analysis was conducted using Stata SE Version 13 (Stata Cor-
poration, College Station, TX, USA) for Windows. For all analyses, a p 
value (two-tailed) of less than 0.05 was considered to indicate statistical 
significance. 
3. Results 
3.1. Descriptive characteristics of the cohort 
Characteristics of the study population according to sex are pre-
sented in Table 1. Significant differences between the sexes were noted 
for education, type 2 diabetes, levels of alcohol consumption and 
physical activity, diet quality and BMI, with male participants having 
fewer protective behaviours than females. Sex differences were also 
observed for all lipoprotein subclasses with the exception of IDL 
concentrations. 
Table 1 
Descriptive characteristics of the study population by sex.  






Age (median) 59.0 
(55.0–64.0) 
59.0 (54.0–64.0) 0.895 
Primary education only (%) 310 (32.7) 227 (23.6) <0.001 
On cholesterol-lowering 
medications (%) 
340 (33.8) 371 (35.7) 0.348 
Type 2 diabetes (%) 118 (11.7) 66 (6.4) <0.001 
Energy intake, kcal (mean) 2034.7 ± 831.9 1994.9 ± 836.1 0.284 
Protective behaviours 
Never or former smoker (%) 841 (85.4) 875 (85.5) 0.923 
Non or moderate drinker (%) 515 (74.6) 518 (96.3) <0.001 
Moderate or high physical 
activity (%) 
528 (57.3) 448 (46.0) <0.001 
DASH diet, upper 40th 
percentile (%) 
226 (24.6) 488 (51.1) <0.001 
BMI, 18.5–24.9 kg/m2 (%) 135 (13.5) 288 (27.8) <0.001 
Number of protective 
behaviours:   
<0.001 
0 or 1 (%) 243 (24.1) 198 (19.1)  
2 (%) 371 (36.8) 324 (31.2)  
3 (%) 279 (27.7) 300 (28.9)  
4 or 5 (%) 114 (11.3) 216 (20.8)  
Lipoprotein particle concentration 
Total TRL, nmol/l (median) 66.5 
(40.4–103.2) 
50.2 (30.6–79.6) <0.001 
Large VLDL, nmol/l (median) 1.4 (0.5–4.3) 0.7 (0.4–2.0) <0.001 




18.1 (8.4–32.4) <0.001 
Small VLDL, nmol/l (median) 33.3 
(18.8–52.4) 
27.9 (15.3–46.2) <0.001 
Total LDL, nmol/l (mean) 1307.0 ± 403.5 1220.8 ± 403.4 <0.001 





Large LDL, nmol/l (mean) 480.3 ± 266.2 705.5 ± 290.6 <0.001 
Small LDL, nmol/l (mean) 710.8 ± 392.8 403.8 ± 376.8 <0.001 
Total HDL, μmol/l (mean) 36.6 ± 5.8 39.9 ± 6.0 <0.001 
Large HDL, μmol/l (median) 4.5 (2.8–6.6) 8.2 (5.6–11.6) <0.001 
Medium HDL, μmol/l (mean) 12.4 ± 5.6 14.6 ± 6.4 <0.001 
Small HDL, μmol/l (mean) 19.2 ± 5.4 16.5 ± 6.1 <0.001 
Lipoprotein particle size 
VLDL size, nm (mean) 46.0 ± 6.6 44.1 ± 5.2 <0.001 
LDL size, nm (mean) 20.6 ± 0.5 21.1 ± 0.5 <0.001 
HDL size, nm (mean) 9.1 ± 0.4 9.5 ± 0.5 <0.001 
LP-IR score (median) 44.0 
(28.0–59.0) 
21.0 (8.0–38.0) <0.001 
TRL: triglyceride-rich lipoprotein; VLDL: very low-density lipoprotein; LDL: low- 
density lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density 
lipoprotein; LP-IR: lipoprotein insulin resistance. 
Mean ± standard deviation or median (interquartile range) are shown for 
continuous variables. Numbers and % (in brackets) for categorical variables will 
vary in different analyses as some variables have missing values. 
p values determined from a Mann Whitney U, Pearson’s chi-square or t-test. 
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3.2. Lipoprotein profiles according to protective lifestyle behaviours 
Table 2 shows characteristics of the study population according to 
the number of protective behaviours. A significant linear association was 
noted between the number of PLB score components and lipoprotein 
particle subclass size and concentration, with mean or median levels 
decreasing or increasing (in the case of large LDL, total HDL, large HDL, 
LDL size and HDL size) with the greater number of protective behav-
iours. For example, the percentage difference in lipoprotein concentra-
tions between having 4 or 5 protective behaviours and 0 or 1 was 150%, 
58.3%, 12.4% and 110.5% for large VLDL, small LDL, small HDL and the 
LP-IR score, respectively. No significant associations were observed 
between the number of protective components and small VLDL and 
medium HDL. Significant linear associations were also observed for the 
age, education and morbidity variables. 
Correlation analysis (Table 3) revealed significant inverse associa-
tions between the PLB score and concentrations of total TRL, large VLDL, 
medium VLDL, total LDL, IDL, small LDL, small HDL, VLDL size and the 
LP-IR score. Large LDL, total HDL, large HDL, LDL size and HDL size 
were positively correlated with the PLB score. Correlations between the 
PLB score and lipoprotein subclasses were stronger for total TRL, large 
LDL and small LDL, with large VLDL, medium VLDL, LDL size and the 
LP-IR score showing the highest correlative strengths. 
3.3. PLB score and lipoprotein profile 
A linear regression analysis exhibiting associations between a PLB 
score and lipoprotein particle subclasses is shown in Table 4. In analyses 
adjusted for age, sex, education and type 2 diabetes, the PLB score 
remained significantly associated with each examined lipoprotein sub-
class with the exception of small VLDL, total HDL and medium HDL. In 
analyses which adjusted for each PLB score component, smoking status 
was significantly inversely related to total TRL, medium VLDL and small 
VLDL concentrations. Non or moderate alcohol use was inversely related 
to large VLDL, IDL, total HDL, large HDL, medium HDL, VLDL and HDL 
size, and was positively associated with total TRL and small VLDL. 
Physical activity levels were inversely related to medium VLDL particle 
concentrations while high diet quality was associated with large VLDL, 
small VLDL, IDL, small HDL, LDL size and the LP-IR score. A normal BMI 
demonstrated the greatest number of significant relationships with li-
poprotein subclasses after adjustment for other protective behaviours. 
Table 5 presents results from logistic regression analyses displaying 
associations between the number of protective behaviours and lipo-
protein particle subclasses. In adjusted models, a dose-response 
Table 2 
Characteristics of the study population according to the number of protective behaviours.  
Feature Number of protective behaviours 
0 or 1 (n = 441) 2 (n = 695) 3 (n = 579) 4 or 5 (n = 330) p trend 
Age (median) 59.0 (55.0–64.0) 60.0 (55.0–64.0) 59.0 (54.0–63.0) 58.0 (54.0–63.0) 0.003 
Primary education only (%) 137 (35.0) 230 (35.2) 124 (22.3) 46 (14.9) <0.001 
On cholesterol-lowering medications (%) 142 (32.2) 258 (37.1) 202 (34.9) 109 (33.0) 0.979 
Type 2 diabetes (%) 58 (13.2) 85 (12.2) 32 (5.5) 9 (2.7) <0.001 
Energy intake, kcal (mean) 1913.8 ± 873.9 2040.0 ± 859.9 2069.3 ± 843.3 1992.2 ± 691.4 0.164 
Never or former smoker (%) 257 (62.8) 596 (86.1) 542 (93.9) 321 (97.3) <0.001 
Non or moderate drinker (%) 51 (37.0) 303 (80.4) 382 (92.0) 297 (99.7) <0.001 
Moderate or high physical activity (%) 28 (7.7) 257 (38.7) 403 (71.6) 298 (90.6) <0.001 
DASH diet, upper 40th percentile (%) 15 (4.2) 133 (21.2) 296 (52.1) 270 (82.8) <0.001 
BMI, 18.5–24.9 kg/m2 (%) 26 (5.9) 101 (14.6) 114 (19.7) 182 (55.3) <0.001 
Total TRL, nmol/l (median) 64.9 (40.6–102.9) 58.0 (36.9–90.4) 55.1 (31.9–85.5) 46.7 (28.6–73.2) <0.001 
Large VLDL, nmol/l (median) 1.5 (0.6–3.9) 1.1 (0.5–3.5) 0.8 (0.4–2.5) 0.6 (0.3–1.5) <0.001 
Medium VLDL, nmol/l (median) 26.6 (14.9–46.9) 23.0 (11.5–38.6) 19.3 (8.5–34.7) 14.6 (6.4–28.0) <0.001 
Small VLDL, nmol/l (median) 32.8 (17.7–51.1) 30.3 (16.5–50.7) 30.4 (17.0–49.8) 28.0 (15.4–47.9) 0.107 
Total LDL, nmol/l (mean) 1311.2 ± 435.8 1278.8 ± 408.4 1240.3 ± 390.5 1205.6 ± 374.9 <0.001 
IDL, nmol/l (median) 99.0 (54.0–166.0) 95.0 (51.0–164.0) 88.0 (49.0–156.0) 86.0 (41.5–141.5) 0.002 
Large LDL, nmol/l (mean) 544.9 ± 300.1 571.6 ± 294.1 602.6 ± 295.4 696.7 ± 300.9 <0.001 
Small LDL, nmol/l (mean) 645.8 ± 438.6 591.3 ± 409.8 525.0 ± 400.2 408.1 ± 368.5 <0.001 
Total HDL, μmol/l (mean) 37.7 ± 6.2 38.4 ± 6.4 38.5 ± 6.0 38.7 ± 5.3 0.037 
Large HDL, μmol/l (median) 5.2 (3.4–8.0) 5.8 (3.7–8.7) 6.4 (3.9–9.9) 8.2 (5.1–14.8) <0.001 
Medium HDL, μmol/l (mean) 13.5 ± 6.0 13.5 ± 6.5 13.4 ± 6.2 13.7 ± 5.6 0.483 
Small HDL, μmol/l (mean) 18.2 ± 5.6 18.3 ± 6.3 17.8 ± 5.7 16.2 ± 5.8 <0.001 
VLDL size, nm (mean) 46.2 ± 6.6 45.4 ± 6.2 44.7 ± 5.7 43.5 ± 5.1 <0.001 
LDL size, nm (mean) 20.7 ± 0.6 20.8 ± 0.5 20.9 ± 0.6 21.1 ± 0.5 <0.001 
HDL size, nm (mean) 9.2 ± 0.5 9.2 ± 0.5 9.3 ± 0.5 9.5 ± 0.5 <0.001 
LP-IR score (median) 40.0 (23.0–58.0) 35.0 (20.0–52.0) 29.0 (12.0–48.0) 19.0 (6.0–37.3) <0.001 
TRL: triglyceride-rich lipoprotein; VLDL: very low-density lipoprotein; LDL: low-density lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density lipo-
protein; LP-IR: lipoprotein insulin resistance. 
Mean ± standard deviation or median (interquartile range) are shown for continuous variables. Numbers and % (in brackets) for categorical variables will vary in 
different analyses as some variables have missing values. 
p for trend determined from a Jonckheere test, a linear-by-linear chi-square or an ANOVA. 
Table 3 
Spearman correlation coefficients between a PLB score and lipoprotein 
subclasses.  
Lipoprotein particle Correlation coefficients p 
Total TRL, nmol/l − 0.140 <0.001 
Large VLDL, nmol/l − 0.192 <0.001 
Medium VLDL, nmol/l − 0.204 <0.001 
Small VLDL, nmol/l − 0.037 0.104 
Total LDL, nmol/l − 0.091 <0.001 
IDL, nmol/l − 0.072 0.001 
Large LDL, nmol/l 0.150 <0.001 
Small LDL, nmol/l − 0.177 <0.001 
Total HDL, μmol/l 0.057 0.011 
Large HDL, μmol/l 0.191 <0.001 
Medium HDL, μmol/l 0.016 0.472 
Small HDL, μmol/l − 0.102 <0.001 
VLDL size, nm − 0.129 <0.001 
LDL size, nm 0.190 <0.001 
HDL size, nm 0.167 <0.001 
LP-IR score − 0.231 <0.001 
TRL: triglyceride-rich lipoprotein; VLDL: very low-density lipoprotein; LDL: low- 
density lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density 
lipoprotein; LP-IR: lipoprotein insulin resistance. 
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Table 4 
Linear regression analysis of the associations between a PLB score, individual protective behaviours and lipoprotein subclasses.  
Feature Log total TRL Log large VLDL Log medium VLDL Log small VLDL 
β ± S.E. p β ± S.E. p β ± S.E. p β ± S.E. p 
PLB score 
Model 1 − 0.07 ± 0.02 0.002 − 0.20 ± 0.03 0.002 − 0.18 ± 0.03 0.002 − 0.01 ± 0.02 .627 
Never or former smoker 
Model 1 − 0.14 ± 0.04 0.004 − 0.16 ± 0.09 .052 − 0.15 ± 0.07 0.03 − 0.16 ± 0.06 0.016 
Model 2 − 0.21 ± 0.06 0.002 − 0.13 ± 0.11 .246 − 0.25 ± 0.09 0.006 − 0.27 ± 0.08 0.004 
Non or moderate drinker 
Model 1 0.10 ± 0.06 0.1 − 0.49 ± 0.11 0.002 − 0.16 ± 0.09 0.052 0.44 ± 0.08 0.002 
Model 2 0.15 ± 0.06 0.02 − 0.43 ± 0.11 0.002 − 0.13 ± 0.09 0.106 0.50 ± 0.09 0.002 
Moderate or high physical activity 
Model 1 − 0.08 ± 0.03 0.008 − 0.19 ± 0.06 0.002 − 0.17 ± 0.05 0.004 − 0.02 ± 0.05 0.683 
Model 2 − 0.07 ± 0.04 0.094 − 0.08 ± 0.08 0.357 − 0.14 ± 0.06 0.024 − 0.04 ± 0.06 0.487 
DASH diet [upper 40th percentile] 
Model 1 − 0.03 ± 0.04 0.315 − 0.19 ± 0.07 0.002 − 0.15 ± 0.05 0.006 0.06 ± 0.05 0.234 
Model 2 0.01 ± 0.05 0.735 − 0.30 ± 0.09 0.002 − 0.09 ± 0.07 0.18 0.13 ± 0.06 0.034 
BMI [18.5–24.9 kg/m2] 
Model 1 − 0.29 ± 0.04 0.002 − 0.67 ± 0.07 0.002 − 0.62 ± 0.06 0.002 − 0.16 ± 0.06 0.01 
Model 2 − 0.31 ± 0.05 0.002 − 0.81 ± 0.10 0.002 − 0.66 ± 0.08 0.002 − 0.18 ± 0.07 0.05  
Feature Total LDL Log IDL Large LDL Small LDL 
β ± S.E. p β ± S.E. p β ± S.E. p β ± S.E. p 
PLB score 
Model 1 − 41.71 ± 9.7 0.002 − 0.10 ± 0.03 0.002 20.92 ± 6.6 0.008 − 55.07 ± 9.2 0.002 
Never or former smoker 
Model 1 − 4.04 ± 21.7 0.898 0.08 ± 0.07 0.254 8.49 ± 18.3 0.661 − 17.17 ± 25.9 0.575 
Model 2 − 3.74 ± 35.3 0.93 0.13 ± 0.10 0.144 21.39 ± 23.0 0.375 − 36.38 ± 32.7 0.331 
Non or moderate drinker 
Model 1 − 4.68 ± 33.9 0.9 − 0.26 ± 0.09 0.004 − 14.40 ± 22.7 0.581 35.59 ± 32.4 0.287 
Model 2 − 16.00 ± 36.4 0.695 − 0.27 ± 0.10 0.012 − 37.04 ± 23.7 0.132 47.28 ± 33.7 0.192 
Moderate or high physical activity 
Model 1 − 38.77 ± 19.5 0.04 − 0.15 ± 0.05 0.006 7.72 ± 13.24 0.565 − 34.38 ± 18.6 0.04 
Model 2 − 24.47 ± 25.6 0.339 − 0.11 ± 0.07 0.116 4.14 ± 16.69 0.796 − 19.05 ± 23.8 0.427 
DASH diet [upper 40th percentile] 
Model 1 − 22.56 ± 21.1 0.295 − 0.17 ± 0.06 0.004 14.98 ± 14.1 0.303 − 26.27 ± 20.1 0.198 
Model 2 − 35.61 ± 27.6 0.186 − 0.19 ± 0.07 0.022 16.59 ± 17.96 0.363 − 36.92 ± 25.6 0.108 
BMI [18.5–24.9 kg/m2] 
Model 1 − 86.24 ± 23.7 0.004 − 0.17 ± 0.06 0.008 123.38 ± 15.8 0.002 − 193.16 ± 22.3 0.002 
Model 2 − 80.32 ± 31.6 0.008 − 0.15 ± 0.09 0.078 155.43 ± 20.6 0.002 − 217.31 ± 29.2 0.002  
Feature Total HDL Log large HDL Medium HDL Small HDL 
β ± S.E. p β ± S.E. p β ± S.E. p β ± S.E. p 
PLB score 
Model 1 − 0.04 ± 0.14 0.778 0.07 ± 0.01 0.002 − 0.23 ± 0.15 0.096 − 0.38 ± 0.14 0.008 
Never or former smoker 
Model 1 − 0.86 ± 0.39 0.07 0.02 ± 0.04 0.689 − 1.14 ± 0.40 0.014 0.15 ± 0.39 0.707 
Model 2 − 0.76 ± 0.51 0.224 0.07 ± 0.05 0.214 − 0.88 ± 0.55 0.118 − 0.35 ± 0.51 0.475 
Non or moderate drinker 
Model 1 − 4.44 ± 0.49 0.002 − 0.16 ± 0.05 0.004 − 3.85 ± 0.52 0.002 0.26 ± 0.50 0.633 
Model 2 − 4.63 ± 0.53 0.002 − 0.19 ± 0.05 0.002 − 4.03 ± 0.56 0.002 0.40 ± 0.53 0.467 
Moderate or high physical activity 
Model 1 0.25 ± 0.29 0.443 0.05 ± 0.03 0.076 − 0.30 ± 0.29 0.331 0.22 ± 0.28 0.463 
Model 2 0.31 ± 0.37 0.447 − 0.06 ± 0.04 0.856 − 0.25 ± 0.40 0.543 0.55 ± 0.37 0.162 
DASH diet [upper 40th percentile] 
Model 1 − 0.84 ± 0.31 0.004 0.003 ± 0.03 0.906 − 0.17 ± 0.32 0.561 − 0.73 ± 0.30 0.018 
Model 2 − 0.71 ± 0.40 0.078 0.004 ± 0.04 0.91 0.26 ± 0.43 0.595 − 0.99 ± 0.40 0.016 
BMI [18.5–24.9 kg/m2] 
Model 1 0.41 ± 0.35 0.264 0.35 ± 0.03 0.002 − 0.25 ± 0.35 0.485 − 1.90 ± 0.33 0.002 
Model 2 0.52 ± 0.46 0.254 0.39 ± 0.05 0.002 − 0.03 ± 0.49 0.952 − 2.26 ± 0.46 0.002  
Feature VLDL size LDL size HDL size Log LP-IR score 
β ± S.E. p β ± S.E. p β ± S.E. p β ± S.E. p 
PLB score 
Model 1 − 0.61 ± 0.16 .002 0.06 ± 0.01 .002 0.06 ± 0.01 .002 − 0.16 ± 0.02 .002 
Never or former smoker 
Model 1 − 0.16 ± 0.43 0.731 0.01 ± 0.03 0.822 0.02 ± 0.03 0.591 − 0.04 ± 0.06 0.499 
Model 2 0.15 ± 0.56 0.824 0.04 ± 0.04 0.377 0.07 ± 0.04 0.074 − 0.08 ± 0.07 0.266 
Non or moderate drinker 
Model 1 − 3.13 ± 0.55 0.002 − 0.04 ± 0.04 0.323 − 0.08 ± 0.04 0.03 − 0.08 ± 0.07 0.238 
Model 2 − 2.78 ± 0.56 0.002 − 0.08 ± 0.04 0.08 − 0.09 ± 0.04 0.024 − 0.04 ± 0.07 0.595 
Moderate or high physical activity 
Model 1 − 0.89 ± 0.31 0.004 0.02 ± 0.02 0.501 0.03 ± 0.02 0.204 − 0.12 ± 0.04 0.006 
Model 2 − 0.46 ± 0.40 0.256 − 0.07 ± 0.03 0.838 − 0.02 ± 0.03 0.493 − 0.03 ± 0.05 0.607 
(continued on next page) 
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relationship was observed; subjects with the fewest number of protective 
behaviours had 1.4–2.8 increased odds of having less favourable lipo-
protein profiles, defined as above or below median level lipoprotein 
particle subclass size or concentration, when compared to individuals 
with 4 or 5. In a final multivariable analysis, which additionally adjusted 
for BMI, significant trend relationships were observed between the 
number of protective behaviours and large VLDL (p = 0.001), medium 
VLDL (p < 0.001), total LDL (p = 0.008), IDL (p = 0.031), small LDL (p <
0.001) concentrations, LDL size (p = 0.003) and the LP-IR score (p =
0.003). 
4. Discussion 
The present study of 2045 middle-to older-aged men and women is 
the first to examine relationships between a multicomponent lifestyle 
score and NMR-derived lipoprotein profiles. Our findings show that 
subjects with the fewest number of protective behaviours (0–1) had 
1.4–2.8 increased odds of having less favourable lipoprotein profiles, 
characterised by more large and medium VLDL particles, more total and 
small LDL particles, smaller LDL size and a greater lipoprotein insulin 
resistance score, when compared to individuals with 4 or 5 protective 
behaviours. Most associations between our five-component PLB score 
and lipoprotein subclass measures remained significant in linear 
regression analyses when adjusted for age, sex, education and type 2 
diabetes. A dose-response relationship between the number of protective 
behaviours and above or below median level lipoprotein particle sub-
class size or concentration was also observed in multivariable logistic 
regression models. These results demonstrate that adopting a healthy 
lifestyle may be an effective approach to improve lipoprotein profiles 
defined by higher or lower subclass concentrations [9,32], attenuate 
atherogenesis, prevent CVD and chronic disease risk and promote 
healthy ageing. 
In our analysis, a greater number of protective behaviours was 
associated with a more favourable lipoprotein profile characterised by 
less large VLDL and smaller LDL particles. Large VLDL and smaller LDL 
particles have been linked to increased risk for atherosclerosis [2,7]. 
Large VLDL particles may be particularly important in terms of CVD risk, 
as they are associated with the pro-atherogenic small dense LDL 
phenotype [2]. Relative to LDL particles, these large lipid-enriched 
VLDL particles are more efficiently hydrolysed by lipoprotein lipase, 
have greater capacity to penetrate the endothelial wall and be prefer-
entially retained in the arterial intima [33]. Hepatic over-production of 
large triglyceride-rich VLDL is a hallmark of dyslipidaemia in obesity 
and insulin resistance, which may initiate diabetic dyslipidaemia [34, 
35]. Furthermore, we report lower LP-IR scores among subjects with a 
greater number of protective behaviours. The LP-IR score is an alter-
native means of assessing a patient’s insulin resistance status based on 
lipoprofile data [22]. 
Examination of individual PLB score components revealed varying 
associations according to lipoprotein subclass. Excluding normal BMI, 
non or moderate alcohol use and diet quality demonstrated the greatest 
number of significant relationships in adjusted linear regression ana-
lyses. Noticeably, the association with alcohol use remained significant 
for nine of the 16 examined measures when additionally adjusted for 
each PLB score component. However, we noted complex relationships 
with alcohol use, with effects that differed according to lipoprotein 
subclass. Non or moderate alcohol use was positively associated with 
total TRL and small VLDL, and was inversely associated with total HDL, 
large HDL, medium HDL and HDL size, suggesting that heavier alcohol 
use is associated with a more favourable profile with regard to these 
lipoprotein subclasses. 
A previous study by Mukamal et al. [36] also found conflicting re-
lationships between alcohol use and lipoproteins. In this research, 
increased alcohol intake was positively associated with large and me-
dium HDL and with lower small VLDL – as our findings also suggest. 
Other studies have also observed greater alcohol consumption to be 
associated with higher HDL concentrations in a dose-response manner 
[37,38]. In a study of 2171 older adults, Muth et al. [39] found highest 
weekly alcohol consumption to be associated with the greatest total HDL 
size and greatest number of medium and large HDL particles, as well as 
higher total HDL concentrations; total small HDL did not differ. In our 
research, we defined alcohol use dichotomously, similar to a method 
employed in a recent research by Li et al. [20]. It is possible that defining 
non or moderate alcohol use with an alternative method may have 
yielded different relationships. 
Our results demonstrating an association between healthy diet and 
lipoprotein profiles are also supported by the literature, although re-
lationships are commonly based on a narrow selection of lipid markers 
[40]. We found healthy diet to be associated with large VLDL, small 
VLDL, IDL, small HDL, LDL size and the LP-IR score. Previous research 
by Phillips et al. [41] revealed a more favourable lipoprotein profile 
characterised by less smaller LDL and small HDL particles and less large 
VLDL particles among those with better diet quality. Importantly, diet 
quality is correlated with weight gain and the research by Phillips et al. 
also showed that risk of central obesity, defined by the 
waist-to-hip-ratio, was lower among subjects in the highest DASH 
quartile compared to the lowest quartile. 
There are limited data available investigating the effects of smoking 
on lipoprotein subclasses. In our study, smoking status was indepen-
dently associated with total TRL, medium VLDL and small VLDL. Using a 
sample of 612 subjects, Beauchamp et al. [42] found female smokers to 
have a more atherogenic lipoprotein profile than non-smokers; these 
results were consistent for both conventional lipid concentrations and 
NMR-determined lipoprotein profiles. However, some sex-specific 
smoking-related changes were observed among males. In a sample of 
1504 participants, Gossett et al. [43] showed smoking to be associated 
with small increases in total cholesterol, LDL, triglycerides and small 
decreases in HDL particle concentrations. As this study also found a 
modest dose-response effect of smoking intensity on lipoprotein con-
centrations, the authors suggested that smoking reduction is unlikely to 
be an effective method for improving lipoproteins among smokers and 
that complete smoking cessation would be a more promising strategy. 
Table 4 (continued ) 
Feature VLDL size LDL size HDL size Log LP-IR score 
β ± S.E. p β ± S.E. p β ± S.E. p β ± S.E. p 
DASH diet [upper 40th percentile] 
Model 1 − 0.40 ± 0.33 0.224 0.05 ± 0.03 0.018 0.02 ± 0.02 .519 − 0.09 ± 0.05 0.049 
Model 2 − 0.67 ± 0.43 0.11 0.06 ± 0.03 0.046 0.01 ± 0.03 0.792 − 0.16 ± 0.05 0.002 
BMI [18.5–24.9 kg/m2] 
Model 1 − 2.12 ± 0.39 0.002 0.22 ± 0.03 0.002 0.29 ± 0.03 0.002 − 0.70 ± 0.05 0.002 
Model 2 − 2.87 ± 0.52 0.002 0.27 ± 0.04 0.002 0.32 ± 0.03 0.002 − 0.83 ± 0.06 0.002 
TRL: triglyceride-rich lipoprotein; VLDL: very low-density lipoprotein; LDL: low-density lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density lipo-
protein; LP-IR: lipoprotein insulin resistance. 
Beta (β) coefficients ± standard errors (S.E.) are shown. 
Model 1: adjusted for age, sex, education and type 2 diabetes. 
Model 2: further adjusted for each protective behaviour. Significant p highlighted in bold. 
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Interestingly, we observed independent associations between mod-
erate or high physical activity levels and only one lipoprotein subclass 
(medium VLDL). As with diet quality, physical activity is correlated with 
body mass. Consequently, the main mechanism by which physical ac-
tivity may improve lipoprotein profiles, and provide protection against 
chronic disease, may be through weight loss. Research by Chrichton 
et al. [44] found higher intensity physical activity to be associated with a 
more favourable lipid profile among normal weight, but not overweight 
or obese subjects. As a high percentage of subjects in our sample were 
overweight/obese (78%), this may partly account for the lack of statis-
tically significant relationships with other lipoprotein subclasses 
observed in our study. 
We noted that having a normal BMI demonstrated the greatest 
number of significant relationships with lipoprotein measures after 
adjustment for other PLB score components, indicating that adiposity is 
strongly related to pro-atherogenic alterations in the lipoprotein sub-
class profile – consistent with previous observations with BMI [3,9]. A 
normal BMI also showed a significant linear association across protec-
tive behaviour categories. This suggests that observed associations be-
tween a PLB score and non-communicable diseases and mortality [20], 
which are mediated by adverse lipoprotein levels, may also largely be 
explained by increased adiposity among subjects with fewer protective 
behaviours. Obesity has long been recognised as a major risk factor for 
CVD and other chronic conditions [45–47]. However, our results 
Table 5 
Logistic regression analysis of the associations between the number of protective behaviours and lipoprotein subclassesa.  
Number of protective behaviours Total TRL Large VLDL Medium VLDL Small VLDL 
OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend 
Model 1 
4 or 5 1 (Reference) 0.001 1 (Reference) <0.001 1 (Reference) <0.001 1 (Reference) 0.329 
3 1.16 (0.86, 1.55)  1.72 (1.27, 2.34)  1.43 (1.06, 1.92)  1.00 (0.75, 1.33)  
2 1.30 (0.98, 1.74)  2.19 (1.62, 2.97)  1.99 (1.49, 2.67)  1.04 (0.79, 1.39)  
0 or 1 1.71 (1.24, 2.35)  2.70 (1.94, 3.76)  2.54 (1.84, 3.51)  1.16 (0.85, 1.59)  
Model 2 
4 or 5 1 (Reference) 0.141 1 (Reference) 0.001 1 (Reference) <0.001 1 (Reference) 0.797 
3 0.93 (0.68, 1.26)  1.22 (0.88, 1.69)  1.04 (0.76, 1.43)  0.92 (0.68, 1.24)  
2 1.02 (0.75, 1.39)  1.50 (1.08, 2.07)  1.40 (1.02, 1.93)  0.95 (0.70, 1.29)  
0 or 1 1.26 (0.90, 1.78)  1.70 (1.19, 2.43)  1.66 (1.17, 2.36)  1.03 (0.74, 1.45)   
Number of protective behaviours Total LDL IDL Large LDL Small LDL 
OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend 
Model 1 
4 or 5 1 (Reference) <0.001 1 (Reference) 0.004 1 (Reference) 0.001 1 (Reference) <0.001 
3 1.21 (0.90, 1.61)  1.08 (0.81, 1.44)  1.49 (1.09, 2.03)  1.74 (1.27, 2.38)  
2 1.48 (1.11, 1.98)  1.34 (1.00, 1.78)  1.70 (1.25, 2.31)  2.23 (1.64, 3.04)  
0 or 1 1.73 (1.26, 2.38)  1.51 (1.10, 2.07)  1.71 (1.22, 2.39)  2.55 (1.81, 3.58)  
Model 2 
4 or 5 1 (Reference) 0.008 1 (Reference) 0.031 1 (Reference) 0.17 1 (Reference) <0.001 
3 1.09 (0.81, 1.49)  1.01 (0.75, 1.36)  1.18 (0.85, 1.63)  1.34 (0.96, 1.87)  
2 1.32 (0.98, 1.80)  1.24 (0.91, 1.67)  1.31 (0.95, 1.82)  1.68 (1.21, 2.34)  
0 or 1 1.51 (1.08, 2.23)  1.37 (0.98, 1.93)  1.25 (0.87, 1.79)  1.79 (1.24, 2.58)   
Number of protective behaviours Total HDL Large HDL Medium HDL Small HDL 
OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend 
Model 1 
4 or 5 1 (Reference) 0.537 1 (Reference) <0.001 1 (Reference) 0.179 1 (Reference) 0.036 
3 0.78 (0.73, 1.31)  1.42 (1.03, 1.96)  0.83 (0.62, 1.11)  1.49 (1.10, 2.00)  
2 0.92 (0.69, 1.23)  1.87 (1.36, 2.56)  0.93 (0.70, 1.25)  1.49 (1.11, 2.00)  
0 or 1 1.13 (0.82, 1.56)  2.21 (1.56, 3.12)  1.20 (0.88, 1.66)  1.43 (1.04, 1.98)  
Model 2 
4 or 5 1 (Reference) 0.762 1 (Reference) 0.069 1 (Reference) 0.342 1 (Reference) 0.514 
3 0.94 (0.69, 1.28)  0.97 (0.68, 1.36)  0.80 (0.59, 1.08)  1.25 (0.91, 1.71)  
2 0.88 (0.65, 1.20)  1.22 (0.87, 1.72)  0.89 (0.66, 1.21)  1.23 (0.90, 1.68)  
0 or 1 1.08 (0.77, 1.53)  1.33 (0.91, 1.93)  1.14 (0.81, 1.61)  1.13 (0.80, 1.60)   
Number of protective behaviours VLDL size LDL size HDL size LP-IR score 
OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend OR (95% CI) p trend 
Model 1 
4 or 5 1 (Reference) 0.027 1 (Reference) <0.001 1 (Reference) <0.001 1 (Reference) <0.001 
3 1.41 (1.02, 1.94)  1.64 (1.18, 2.29)  1.27 (0.93, 1.73)  1.53 (1.11, 2.11)  
2 1.37 (1.00, 1.88)  2.12 (1.53, 2.94)  1.68 (1.24, 2.28)  2.27 (1.65, 3.11)  
0 or 1 1.51 (1.07, 2.13)  2.39 (1.68, 3.42)  1.79 (1.28, 2.49)  2.79 (1.97, 3.95)  
Model 2 
4 or 5 1 (Reference) 0.854 1 (Reference) 0.003 1 (Reference) 0.279 1 (Reference) 0.003 
3 1.09 (0.78, 1.54)  1.26 (0.89, 1.79)  0.90 (0.64, 1.25)  1.01 (0.71, 1.42)  
2 1.02 (0.73, 1.43)  1.59 (1.12, 2.25)  1.16 (0.83, 1.61)  1.44 (1.02, 2.03)  
0 or 1 1.06 (0.73, 1.54)  1.68 (1.15, 2.46)  1.13 (0.79, 1.62)  1.61 (1.11, 2.34)  
TRL: triglyceride-rich lipoprotein; VLDL: very low-density lipoprotein; LDL: low-density lipoprotein; IDL: intermediate-density lipoprotein; HDL: high-density lipo-
protein; LP-IR: lipoprotein insulin resistance. 
Odds ratios (OR) and 95% confidence intervals (CI) are shown. 
Model 1: adjusted for age, sex, education and type 2 diabetes. 
Model 2: further adjusted for normal BMI (18.5–24.9 kg/m2). 
a Above median except for large LDL, total HDL, large HDL, LDL size and HDL size (below median). 
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demonstrate significant trend relationships between the number of 
protective behaviours and large VLDL, medium VLDL, total LDL, IDL, 
small LDL, LDL size and the LP-IR score. Furthermore, in multivariable 
logistic regression models adjusted for BMI, these findings show a cu-
mulative protective effect against metabolic dysregulation that is inde-
pendent of having a healthy body weight. 
4.1. Strengths and limitations 
Research on protective behaviours is of public health importance. 
Such investigation contributes to the knowledge base and may inform 
public health guidelines and policy. As far as we are aware, this research 
is the first to test a five-component PLB score (and individual PLB score 
component) associations with 15 lipoprotein subclasses and the LP-IR 
score. Other strengths include the large number of middle-to older- 
aged study participants, equal representation by sex (49% male) and the 
use of validated questionnaires to collect a wide range of diet, lifestyle 
and phenotypic data. With the elderly population growing [48], it is to 
be expected that the number of patients with non-communicable dis-
eases will increase. Importantly, our findings suggest that modifications 
in certain lifestyle behaviours and adopting a healthier diet may have 
potential cardioprotective effects, which may be of particular impor-
tance to older adults. 
Despite these strengths, several limitations should be noted. The 
cross-sectional study design limits inference with regards to causality 
and precludes drawing conclusions regarding the temporal direction of 
relationships. Moreover, the use of self-reported questionnaires is sub-
ject to potential inaccuracies, recall and reporting bias and residual 
confounding arising from imprecise measurement of variables should 
also be considered. Data were collected from a single primary care-based 
sample, which may not be representative of the general population. 
However, previous research suggests that approximately 98% of Irish 
adults are registered with a GP and that, even in the absence of a uni-
versal patient registration system, it is possible to perform population- 
based epidemiological studies that are representative using our 
methods [49]. 
4.2. Conclusions 
In conclusion, our findings show that in middle-to older aged adults a 
combination of protective behaviours may potentially confer car-
dioprotective benefits, which could attenuate dyslipidaemia and related 
metabolic dysregulation. As an unfavourable lipoprotein profile may 
precede many non-communicable diseases, these data highlight the 
potential benefits of following a healthy lifestyle and maintaining a BMI 
in the normal range. Improving our understanding of the relationships 
between protective behaviours and biomarkers of health is warranted, 
with a view to informing public health planning and policy to improve 
and maintain optimal cardiometabolic health at a population level. 
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